Mortality After Cryptococcal Infection in the Modern Antiretroviral Therapy Era.

Background: The prevalence of cryptococcosis in people living with HIV (PLWH) in the developed world has decreased considerably in the modern antiretroviral therapy (ART) era. Although early mortality of PLWH with opportunistic infections is well understood, overall mortality has not been previously evaluated.

Methods: We conducted a retrospective cohort study of cryptococcosis in PLWH from January 1, 2002, to July 1, 2017.

Presentation and Mortality of Cryptococcal Infection Varies by Predisposing Illness: A Retrospective Cohort Study.

Background: Cryptococcal epidemiology is changing in the modern antiretroviral era, and immune status informs outcomes. We describe the differences in clinical presentation and mortality of cryptococcosis by immune status in the antiretroviral therapy era.

Methods: We conducted a single-center retrospective cohort study of patients diagnosed with cryptococcosis from 2002 through 2017.

Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV.

Background: An infectious disease (ID) consultation is often obtained to treat patients with cryptococcosis due to the complex nature of the disease, but has never been demonstrated to impact outcomes.

Methods: We assembled a retrospective cohort of 147 consecutive cases of cryptococcosis in patients without HIV. Patients who were diagnosed less than 24 hours prior to death were excluded.

End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis.

Background.  Cryptococcosis in the setting of end-stage liver disease (ESLD) has been associated with high mortality. We sought to compare the outcome of cryptococcal disease in patients with ESLD to that of human immunodeficiency virus (HIV)-positive patients and to those patients without HIV or ESLD.

Preparation and evaluation of cilnidipine microemulsion.

Cilnidipine, a calcium channel blocker having neuroprotective action and BCS Class II drug, hence formulating in Microemulsion will increase solubility, absorption and bioavailability. The formulation was prepared using titration method by tocotrienol, tween 20 and transcutol HP as oil, surfactant and co-surfactant and characterized for dilutability, dye solubility, assay (98.39±0.